Thermo Fisher Scientific (NYSE:TMO) Price Target Raised to $654.00

Thermo Fisher Scientific (NYSE:TMO) had its price target upped by TD Cowen from $612.00 to $654.00 in a research note published on Thursday morning,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

A number of other equities research analysts also recently weighed in on the company. Hsbc Global Res downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Wells Fargo & Company upped their target price on shares of Thermo Fisher Scientific from $565.00 to $635.00 and gave the company an “overweight” rating in a research report on Thursday. William Blair initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an “outperform” rating on the stock. Scotiabank upgraded shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 target price for the company in a research report on Friday, July 11th. Finally, Leerink Partners raised their price target on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research report on Wednesday. Nineteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $595.75.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $573.07 on Thursday. Thermo Fisher Scientific has a 12-month low of $385.46 and a 12-month high of $610.97. The stock has a 50-day simple moving average of $504.04 and a 200 day simple moving average of $453.55. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $216.40 billion, a price-to-earnings ratio of 33.11, a P/E/G ratio of 3.24 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The company had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company’s revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the firm posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, research analysts anticipate that Thermo Fisher Scientific will post 23.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the transaction, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. The trade was a 0.35% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 29,666 shares of company stock worth $13,990,971 in the last ninety days. 0.33% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

Several institutional investors have recently added to or reduced their stakes in TMO. CBIZ Investment Advisory Services LLC grew its holdings in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after buying an additional 33 shares in the last quarter. Highline Wealth Partners LLC grew its stake in shares of Thermo Fisher Scientific by 126.9% during the 3rd quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock worth $29,000 after acquiring an additional 33 shares in the last quarter. Anderson Financial Strategies LLC acquired a new stake in shares of Thermo Fisher Scientific in the first quarter valued at approximately $30,000. Keystone Global Partners LLC bought a new stake in shares of Thermo Fisher Scientific in the first quarter worth $31,000. Finally, IMA Advisory Services Inc. bought a new position in Thermo Fisher Scientific in the first quarter valued at $35,000. 89.23% of the stock is owned by institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.